Siste måned

30 dager
0
NETTO POSISJON (NOK)
Handler
1
Kjøp
0
Salg
0

6 måneder

180 dager
+1 902 330
NETTO POSISJON (NOK)
Handler
14
Kjøp
1 902 330
Salg
0

Historikk

ℹ️ Om innsidehandel

Primærinnsidere er personer med ledelsesansvar og deres nærstående. Meldeplikt inntrer når transaksjoner når EUR 5 000 i et kalenderår.

Meldefrist: umiddelbart, senest tre virkedager. Handelsforbud 30 dager før pliktig finansiell rapportering.

Transaksjoner

Dato Innsider Antall Pris Verdi
28.10.2026
Zuzana Jiráková Trnková
Chief Medical Officer
20 000 - -
22.09.2026
Øystein Soug
Chief Executive Officer
142 90.00 12 780
22.09.2026
Øystein Soug
Chief Executive Officer
via Abakus Invest AS
3 333 90.00 299 970
22.09.2026
Ramzi Amri
Chief Financial Officer
3 000 90.00 270 000
22.09.2026
Charles Gillies O'Bryan-Tear
Chairman of the Board of Directors
9 846 90.00 886 140
22.09.2026
Gro Hjellum
Chief Operating Officer
500 90.00 45 000
22.09.2026
Ingrid Akay
Member of the Board of Directors
via Teakay Invest AS
3 984 90.00 358 560
22.09.2026
Kari Grønås
Member of the Board of Directors
via K OG K AS
332 90.00 29 880
20.05.2026
Kari Grønås
Board member
854 - -
20.05.2026
Hilde Steineger
Board member
854 - -
20.05.2026
Johan Häggblad
Board member
854 - -
20.05.2026
Olav Hellebø
Board member
1 408 - -
20.05.2026
Orlando Oliveira
Board member
854 - -
20.05.2026
Charles Gillies O'Bryan-Tear
Chairperson of the Board
1 708 - -
11.03.2026
Øystein Soug
CEO
31 884 - -
12.01.2026
Ramzi Amri
CFO
5 430 000 0.50 2 715 000
Vis alle 16 transaksjoner ▼

Pressemeldinger

Dato Melding
28.10.2026
Oncoinvent ASA: Grant of share options to new Chief Medical Officer
Oslo, Norway, 28 October 2026: Oncoinvent has granted the new Chief Medical Officer (CMO) Dr Zuzana Jirakova Trnkova 20,000 share options in the Compa...
23.09.2026
Oncoinvent ASA - Mandatory notification of trade
Reference is made to the retail offering (the "Retail Offering") announced by Oncoinvent ASA on 22 September 2026. Please see the attached PDMR-form r...
22.09.2026
Oncoinvent ASA - Mandatory notification of trade
Reference is made to the private placement (the "Private Placement") announced by Oncoinvent ASA on 22 September 2026. Please see the attached PDMR-fo...
20.05.2026
Oncoinvent ASA: Grant of share options to member of the Board following AGM
Oslo, Norway, 20 May 2026: Reference is made to the Annual General Meeting (the "AGM") of Oncoinvent ASA (the "Company") earlier today where the nomin...
11.03.2026
Oncoinvent ASA: Grant of share options to the CEO
Oslo, Norway, 11 March 2026: The Board of Directors has today resolved to grant CEO Øystein Soug 31,884 share options in the Company under the Company...
13.01.2026
Oncoinvent ASA: Grant of share options to new CFO
Oslo, Norway, 13 January 2026: Reference is made to the announcement made by Oncoinvent ASA ("Oncoinvent" or the "Company") 31 October 2025 regarding ...
Vis alle 6 meldinger ▼